Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10078895 | 0.89 | CES2 (0.40) | ALDH1A1TDP1TSHR | |
| SCHEMBL10212353 | 0.89 | PTGS1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL13542695 | 0.88 | MEN1 (0.37) | ALDH1A1TDP1TSHRMEN1KMT2A | |
| SCHEMBL23696048 | 0.86 | MEN1 (0.40) | ALDH1A1TDP1TSHRMEN1KMT2A | |
| SCHEMBL22856475 | 0.86 | MEN1 (0.40) | ALDH1A1TDP1TSHRMEN1KMT2A | |
| SCHEMBL10165857 | 0.86 | — | — | |
| SCHEMBL23696339 | 0.86 | MEN1 (0.40) | ALDH1A1TDP1TSHRMEN1KMT2A | |
| SCHEMBL24704073 | 0.85 | TDP1 (0.39) | TDP1 | |
| SCHEMBL24448682 | 0.84 | — | — | |
| SCHEMBL21564105 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522619-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4463462-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118715231-A | Complement factor inhibitors and uses thereof | 安尼艾克松股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | STARPHARMA PTY LTD (AU) | 2023-08-24 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2023137166-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023137166-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20220395525-A1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD. (AU) | 2022-12-15 | — | — | US | disclosed |
| US-8648094-B2 | IAP BIR domain binding compounds | PHARMASCIENCE, INC. (CA) | 2014-02-11 | — | — | US | disclosed |
| US-20120195915-A1 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2012-08-02 | — | — | US | disclosed |
| US-8163792-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2012-04-24 | — | — | US | disclosed |
| US-20100203012-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-08-12 | — | — | US | disclosed |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100203012-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | ALDH1A1 3602/4885TDP1 842/4885TSHR 4151/4885 |
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | SARS1, MMAB, PAM | ALDH1A1 2061/4885TDP1 3076/4885TSHR 2979/4885 |
| US-20120195915-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | ALDH1A1 3380/4885TDP1 370/4885TSHR 3389/4885 |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | ALDH1A1 3380/4885TDP1 370/4885TSHR 3389/4885 |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | ALDH1A1 653/4885TDP1 1413/4885TSHR 2377/4885 |
| US-20220395525-A1 | THERAPEUTIC DENDRIMER | DCK, PAICS, SAMHD1 | ALDH1A1 1769/4885TDP1 732/4885TSHR 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.